Skip to main content
. 2025 Nov 25;14(23):8366. doi: 10.3390/jcm14238366
PRISMA Preferred Reporting Items For Systematic Reviews And Meta-Analyses
EC Endometrial Cancer
PFS Progression-free survival
OS Overall Survival
ORR Objective Response Rate
DFS Disease-free survival
TRAE Treatment-related adverse event
AE Adverse event
i.v. intravenous